Cue Biopharma, Inc.

As of June 30, 2026, Cue Biopharma, Inc. carries a market capitalization of 143.39M, placing it among publicly traded companies globally. Its enterprise value stands at 130.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cue Biopharma, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Cue Biopharma, Inc. has 5.23M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.77, and the price-to-book ratio stands at 70.92.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 130.86M versus a market cap of 143.39M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cue Biopharma, Inc. maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 133.20, indicating elevated leverage, while an interest coverage ratio of -707.60 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Cue Biopharma, Inc. posted a negative return on equity (ROE) of -1,603.48, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -459.60, reflecting losses generated across the asset base. The company generates approximately 1.03M in revenue per employee across its workforce of 32.00, a quick read on workforce productivity versus industry peers.

These figures are as of the close on October 23, 2026.

Over the twelve months ended June 30, 2026, Cue Biopharma, Inc. generated 32.96M in revenue and converted that into -143.64M in net income, yielding earnings per share of -31.58. EBITDA reached -83.61M, while operating income came in at -86.34M.

As of June 30, 2026, Cue Biopharma, Inc. holds 15.22M in cash and equivalents against 2.69M in total debt, resulting in a net debt position of -15.22M. Total book value stands at 2.02M, with working capital of 4.73M providing operational flexibility.

Cue Biopharma, Inc. produced -43.81M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -105,911.30 in capital expenditures, free cash flow totaled -43.91M - equivalent to -9.70 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -261.97 and net profit margin of -435.83 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -35.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -24.31, meaning Cue Biopharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Cue Biopharma, Inc.'s most recent stock split took place on April 24, 2026 with a 30:1 split ratio.

As of June 30, 2026, Cue Biopharma, Inc. has an Altman Z-Score of -29.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.